STOCK TITAN

BioCryst Pharmaceuticals Inc - BCRX STOCK NEWS

Welcome to our dedicated page for BioCryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on BioCryst Pharmaceuticals stock.

BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) is a global biotechnology company dedicated to improving the lives of individuals living with rare and serious diseases. Founded in 1986, BioCryst specializes in designing, optimizing, and developing novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. Headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama, the company harnesses its expertise in drug discovery, clinical development, regulatory affairs, and product commercialization.

BioCryst is known for its flagship product, ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor specifically designed to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 12 years and older. The efficacy of ORLADEYO has been demonstrated through multiple clinical studies and real-world data, showing significant reductions in HAE attack rates across various patient profiles.

The company's robust pipeline includes several innovative programs such as BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME). BioCryst's research spans multiple scientific disciplines, including biology, computer modeling, and medicinal chemistry, targeting therapeutic areas like acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.

In recent announcements, BioCryst reported strong financial performance with ORLADEYO net revenue experiencing substantial growth. The company also continues to expand globally, with recent approvals of ORLADEYO in major markets, including Brazil and Mexico. Partnerships with organizations such as Pint Pharma help BioCryst extend its reach and bring life-changing treatments to patients worldwide.

BioCryst remains committed to advancing its clinical programs, generating new compounds, and upholding a culture of engagement and accountability. The company's ongoing dedication to developing innovative therapeutics aims to address unmet medical needs and provide better health outcomes for patients suffering from rare and serious conditions.

For more information, please visit www.biocryst.com or follow them on LinkedIn.

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has announced a pause in the enrollment of new patients in its clinical trials for BCX9930 due to elevated serum creatinine levels observed in some participants. This affects the REDEEM-1, REDEEM-2, and RENEW trials, although current participants will continue their treatment. The company is investigating these safety concerns before proceeding further. BioCryst develops medicines for rare diseases and continues to progress with other drugs in its pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.81%
Tags
-
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) granted stock options and restricted stock units (RSUs) to 19 newly-hired employees on March 31, 2022. The total stock options cover 124,800 shares and RSUs cover 47,400 shares, with an exercise price of $16.26 per share, equivalent to the closing stock price on the grant date. The options and RSUs vest annually over four years, contingent on continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and aligns with BioCryst’s Inducement Equity Incentive Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in upcoming healthcare conferences. The company will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. ET and at the Barclays Global Healthcare Conference in Miami Beach, Florida, on March 16, 2022, at 2:35 p.m. ET. Both presentations will be available via live audio webcast on BioCryst's website. The company focuses on developing innovative treatments for rare diseases, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
conferences
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced the grant of stock options and restricted stock units (RSUs) to 17 new employees, totaling 290,000 shares. The options have an exercise price of $16.61, aligned with the closing stock price on February 28, 2022. These grants aim to attract talent as part of Nasdaq Listing Rule 5635(c)(4). The options and RSUs will vest over four years, contingent on continued employment. BioCryst specializes in oral treatments for rare diseases and continues to advance its product pipeline including ORLADEYO and BCX9930.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced promising long-term efficacy and safety results from the APeX-2 trial of ORLADEYO (berotralstat), aimed at treating hereditary angioedema (HAE). Data presented at the 2022 AAAAI annual meeting revealed that patients had a remarkable average of 94 percent attack-free days over 96 weeks. The study involved 121 patients, showing sustained attack rate reductions across various groups. ORLADEYO was well-tolerated, with no serious adverse events, suggesting its potential as an effective prophylactic therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals reported Q4 2021 revenues of $47.2 million, driven largely by $46.2 million from ORLADEYO, marking a significant increase from $4 million in Q4 2020. For FY 2021, total revenues reached $157.2 million, with ORLADEYO contributing $122.6 million. The company anticipates 2022 ORLADEYO revenues of no less than $250 million. With over $500 million in cash, BioCryst plans to expand its pipeline, focusing on the advancements in its Factor D programs for rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has enrolled its first patient in the RENEW study, aimed at assessing the oral Factor D inhibitor, BCX9930, in renal diseases such as C3 glomerulopathy, IgAN, and PMN. This multicenter trial will involve about 42 patients receiving BCX9930 over 24 weeks, with the primary endpoint being the change in urine protein-to-creatinine ratio. The company is also advancing its clinical efforts with BCX9930 in ongoing REDEEM trials for PNH, seeking to establish regulatory approvals over the next two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
none
-
Rhea-AI Summary

BioCryst Pharmaceuticals, Inc. (BCRX) plans to release its fourth quarter and full year 2021 financial results on February 23, 2022. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call via telephone or online, with a replay available afterward. BioCryst specializes in discovering novel oral medicines for rare diseases, with products like ORLADEYO and ongoing development programs targeting complement-mediated diseases and viral infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences earnings
-
Rhea-AI Summary

BioCryst Pharmaceuticals has appointed Machelle Sanders, North Carolina Secretary of Commerce and a veteran in pharmaceutical operations, to its board of directors. With over 30 years of experience, including leadership roles at Biogen, Sanders brings extensive expertise in scaling operations while maintaining quality control. Her appointment comes as BioCryst builds on the success of ORLADEYO, its recently launched oral treatment for rare diseases. Sanders emphasized the potential for growth through effective commercialization and innovation in R&D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
management
Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced the grant of stock options and restricted stock units (RSUs) to 31 newly-hired employees, totaling 213,500 shares in options and 24,700 shares in RSUs. The options have an exercise price of $15.45 per share, equal to the stock's closing price on January 31, 2022. Vesting occurs in four equal annual installments, starting one year after the grant date, contingent upon continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent within the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none

FAQ

What is the current stock price of BioCryst Pharmaceuticals (BCRX)?

The current stock price of BioCryst Pharmaceuticals (BCRX) is $7.93 as of January 13, 2025.

What is the market cap of BioCryst Pharmaceuticals (BCRX)?

The market cap of BioCryst Pharmaceuticals (BCRX) is approximately 1.6B.

What is BioCryst Pharmaceuticals' main product?

BioCryst Pharmaceuticals' main product is ORLADEYO® (berotralstat), an oral, once-daily plasma kallikrein inhibitor designed to prevent attacks of hereditary angioedema (HAE).

Where is BioCryst Pharmaceuticals headquartered?

BioCryst Pharmaceuticals is headquartered in Research Triangle Park, North Carolina, with a discovery center in Birmingham, Alabama.

What therapeutic areas does BioCryst Pharmaceuticals focus on?

BioCryst Pharmaceuticals focuses on therapeutic areas such as acute uncomplicated influenza, hereditary angioedema, filoviruses (Ebola and Marburg), and oncology.

What recent achievements has BioCryst Pharmaceuticals reported?

BioCryst Pharmaceuticals has reported strong financial performance with significant growth in ORLADEYO® net revenue and recent approvals of ORLADEYO in Brazil and Mexico.

How does ORLADEYO® work?

ORLADEYO® works by decreasing the activity of plasma kallikrein, thereby preventing hereditary angioedema (HAE) attacks.

What is the pipeline of BioCryst Pharmaceuticals?

The pipeline of BioCryst Pharmaceuticals includes programs like BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME).

Who are BioCryst Pharmaceuticals' partners?

BioCryst Pharmaceuticals partners with organizations such as Pint Pharma to extend their reach and bring treatments to patients worldwide.

What is the company's approach to drug development?

BioCryst Pharmaceuticals leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases.

What are some of the challenges BioCryst Pharmaceuticals addresses?

BioCryst Pharmaceuticals addresses challenges in rare and serious diseases by developing innovative therapeutics to meet unmet medical needs and improve health outcomes.

How can I stay updated on BioCryst Pharmaceuticals' latest news?

You can stay updated on BioCryst Pharmaceuticals' latest news by visiting their website at www.biocryst.com or following them on LinkedIn.
BioCryst Pharmaceuticals Inc

Nasdaq:BCRX

BCRX Rankings

BCRX Stock Data

1.62B
200.27M
1.46%
85.11%
8.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DURHAM